Open Access Open Access  Restricted Access Subscription or Fee Access

Hydromorphone use for acute pain: Misconceptions, controversies, and risks

Maryann Mazer-Amirshahi, PharmD, MD, MPH, Sergey Motov, MD, Lewis S. Nelson, MD

Abstract


Hydromorphone (HM) is a potent opioid analgesic that is commonly administered in the emergency department (ED) and other acute care settings, such as medical surgical wards. In recent years, there has been a significant increase in the ED administration of HM relative to other opioids. Although HM is an effective analgesic, its use has been commonly implicated in adverse drug events and medication errors. In addition, intravenous HM has potent euphoric effects that may contribute to its abuse liability. There are limited data regarding how acute parenteral administration of opioid analgesics in the setting of high rates of preexisting chronic opioid use (medical or nonmedical) may contribute to or reinforce addictive behavior, making the potential contribution of rising HM administration to subsequent prescription opioid abuse and overdose uncertain. This review addresses the pharmacology of HM, recommended dosing, its efficacy for acute pain, as well as its tolerability, safety, and abuse profiles. Controversies and strategies for appropriate use of this medication are also described.


Keywords


HM, ED

Full Text:

PDF

References


Mazer-Amirshahi M, Mullins PM, Rasooly I, et al.: Rising opioid prescribing in adult U.S. emergency department visits: 2001-2010. Acad Emerg Med. 2014; 21: 236-243.

Mazer-Amirshahi M, Dewey K, Mullins PM, et al.: Trends in opioid analgesic use for headaches in U.S. emergency departments. Am J Emerg Med. 2014; 32: 1068-1073.

Mazer-Amirshahi M, Mullins PM, Rasooly IR, et al.: Trends in prescription opioid use in pediatric emergency departments. Pediatr Emerg Care. 2014; 30: 230-235.

Kea B, Fu R, Lowe RA, et al.: Interpreting the National Hospital Ambulatory Medical Care Survey; United States opioid prescribing, 2006-2010. Acad Emerg Med. 2016; 23: 159-165.

Maxwell JC: The prescription drug epidemic in the United States: A perfect storm. Drug Alcohol Rev. 2011; 30: 264-270.

Manchikanti L, Helm S 2nd, Fellows B, et al.: Opioid epidemic in the United States. Pain Phys. 2012; 15(suppl 3): ES9-ES38.

Phillips DM: JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations. JAMA. 2000; 284: 428-429.

Schwartz RK, Soumerai SB, Avorn J: Physician motivations for nonscientific drug prescribing. Soc Sci Med. 1989; 28: 577-582.

Centers for Disease Control and Prevention. Prescription opioid overdose data. Available at http://www.cdc.gov/drugoverdose/data/overdose.html. Accessed August 6, 1016.

Beaudoin FL, Merchant RC, Janicki A, et al.: Preventing iatrogenic overdose: A review of in-emergency department opioid-related adverse drug events and medication errors. Ann Emerg Med. 2015; 65: 423-431.

Gulseth MP, Meisel S, Meisel M: Increasing the safety of analgesia use in a community hospital. Am J Health Syst Pharm. 2004; 61: 1143-1146.

Neil K, Marcil A, Kosar L, et al.: Retrospective analysis of opioid medication incidents requiring the administration of naloxone. Can J Hosp Pharm. 2013; 66: 280-288.

Lail S, Sequeira K, Lieu J, et al.: Prescription of opioids for opioid-naive medical inpatients. Can J Hosp Pharm. 2014; 67: 337-342.

Ricket A, Mateyoke G, Vallabh M, et al.: A pilot evaluation of a hydromorphone dose substitution policy and the effects on patient safety and pain management. J Pain Palliat Care Pharmacother. 2015; 29: 120-124.

Butler MM, Ancona RM, Beauchamp GA, et al.: Emergency department prescription opioids as an initial exposure preceding addiction. Ann Emerg Med. 2016; 68: 202-208.

Sellers EM, Schuller R, Romach MK, et al.: Relative abuse potential of opioid formulations in Canada: A structured field study. J Opioid Manag. 2006; 2: 219-227.

Chang AK, Bijur PE, Meyer RH, et al.: Safety and efficacy of hydromorphone as an analgesic alternative to morphine in acute pain: A randomized clinical trial. Ann Emerg Med. 2006; 48: 164-172.

Chang AK, Bijur PE, Napolitano A, et al.: Two milligrams i.v. hydromorphone is efficacious for treating pain but is associated with oxygen desaturation. J Opioid Manag. 2009; 5: 75-80.

Lowe A, Hamilton M, Greenall, et al.: Fatal overdoses involving hydromorphone and morphine among inpatients: a case series. CMAJ Open. 2017; 5: E184-E189.

Sarhill N, Walsh D, Nelson KA: Hydromorphone: Pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001; 9: 84-96.

Gregory TB: Hydromorphone: Evolving to meet the challenges of today's healthcare environment. Clin Ther. 2013; 35: 2007-2017.

Knotkova H, Fine PG, Portenoy RK: Opioid rotation: The science and the limitations of the equianalgesic dose table. J Pain Symptom Manag. 2009; 38: 426-439.

Vallner JJ, Stewart JT, Kotzan JA, et al.: Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol. 1981; 214: 152-156.

Sutter ME, Wintemute GJ, Clarke SO, et al.: The changing use of intravenous opioids in an emergency department. West J Emerg Med. 2015; 16: 1079-1083.

Exalgo (hydromorphone) prescribing information. Available at http://www2.mallinckrodt.com/Templates/Pages/productdetail.aspx?id=2147483738. Accessed August 27, 2016.

FDA asks Purdue Pharma to withdraw Palladone for safety reasons [press release]. July 13, 2005. Silver Spring, MD: US Food and Drug Administration. Available at www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108460.htm. Accessed August 27, 2016.

Murray S, Wooltorton E: Alcohol-associated rapid release of a long-acting opioid. CMAJ. 2005; 173: 756.

Trescot AM, Datta S, Lee M, et al.: Opioid pharmacology. Pain Phys. 2008; 11: S133-S153.

Vallner JJ, Stewart JT, Kotzan JA, et al.: Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol. 1981; 21: 152-156.

Coda B, Tanaka A, Jacobson RC, et al.: Hydromorphone analgesia after intravenous bolus administration. Pain. 1997; 71: 41-48.

Vallejo R, Barkin RL, Wang VC: Pharmacology of opioids in the treatment of chronic pain syndromes. Pain Phys. 2011; 14: E343-E360.

Babul N, Darke AC, Hagen N: Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manag. 1995; 10: 184-186.

Fainsinger R, Schoeller T, Boiskin M, et al.: Palliative care rounds: Cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care. 1993; 9: 53-55.

Paramanadam G, Prommer E, Schwenke DC: Adverse effects in hospice patients with chronic kidney disease. J Palliat Med. 2011; 14: 1029-1033.

Wright AW, Mather LE, Smith, MT: Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci. 2001; 69: 409-420.

Dilaudid HP prescribing information. Available at https://www.drugs.com/dosage/dilaudid-hp.html. Accessed September 20, 2016.

Dilaudid prescribing information. Available at https://www.drugs.com/pro/dilaudid.html. Accessed September 20, 2016.

Xia S, Choe D, Hernandez L, et al.: Does initial hydromorphone relieve pain best if dosing is fixed or weight based? Ann Emerg Med. 2014; 63: 692-698(e4).

Chang AK, Bijur PE, Campbell CM, et al.: Safety and efficacy of rapid titration using 1 mg doses of intravenous hydromorphone in emergency department patients with acute severe pain: The 1 + 1 protocol. Ann Emerg Med. 2009; 54: 221-225.

Chang AK, Bijur PE, Gallager J: Randomized clinical trial comparing the safety and efficacy of a hydromorphone titration protocol to usual care in the management of adult emergency department patients with acute severe pain. Ann Emerg Med. 2011; 58: 352-359.

Chang AK, Bijur PE, Lupow JB, et al.: Randomized clinical trial of the 2-mg hydromorphone bolus protocol versus the “1 + 1” hydromorphone titration protocol in treatment of acute, severe pain in the first hour of emergency department presentation. Ann Emerg Med. 2013; 64: 305-310.

Chang AK, Bijur PE, Holden L, et al.: Efficacy of an acute pain titration protocol driven by patient response to a simple query: Do you want more pain medication? Ann Emerg Med. 2016; 67: 565-572.

Chang AK, Bijur PE, Lupow JB, et al.: Randomized clinical trial of efficacy and safety of a single 2 mg intravenous dose of hydromorphone versus usual care in the management of acute pain. Acad Emerg Med. 2013; 20: 185-192.

Felden L, Walter C, Harder S, et al.: Comparative clinical effects of hydromorphone and morphine: A meta-analysis. BJ Anaesth. 2011; 107: 319-328.

Chang AK, Bijur PE, Baccelieri A, et al.: Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: A prospective, randomized, double-blind clinical trial. Am J Geriatr Pharmacother. 2009; 7: 1-10.

O'Connor AB, Lang VJ, Quill TE: Underdosing of morphine in comparison with other parenteral opioids in an acute hospital: A quality of care challenge. Pain Med. 2006; 7: 299-307.

Paparella S: Intravenous HYDROmorphone: Can you manage the risk? J Emerg Nurs. 2011; 37: 377-380.

Controlled Substance Staff. Background Materials for September 9-10, 2003 ALSDAC Meeting. Available at http://www.fda.gov/ohrms/dockets/ac/03/briefing/3978B1_05_AFDA-Tab%204.pdf. Accessed September 28, 2016.

US Department of Justice, Quotas, US Department of Justice Drug Enforcement Administration, Springfield, VA, USA, 2012, Available at http://www.deadiversion.usdoj.gov/quotas/index.html. Accessed September 28, 2016.

Fischer B, Jones W, Urbanoski K, et al.: Correlations between prescription opioid analgesic dispensing levels and related mortality and morbidity in Ontario, Canada, 2005-2011. Drug Alcohol Rev. 2014; 33: 19-26.

Dy SM, Shore AD, Hicks RW, et al.: Medication errors with opioids: Results from a national reporting system. J Opioid Manag. 2007; 3(4): 189-194.

Pennsylvania Patient Safety Authority. Adverse drug events with HYDROmorphone: How preventable are they? PA Patient Saf Advisory. 2010; 7: 69-75.

Deitch K, Domingo G, Kowalski M, et al.: 318 The 1 plus 1 hydromorphone pain protocol has similar efficacy as physician discretion analgesia and is less safe in older adults: A randomized trial. ACEP 2015 abstracts. Available at http://www.annemergmed.com/article/S0196-0644(15)00944-0/abstract. Accessed September 28, 2016.

O'Connor AB, Zwemer FL, Hays DP, et al.: Intravenous opioid dosing and outcomes in emergency patients: A prospective cohort analysis. Am J Emerg Med. 2010; 28: 1041-1050.

Beaudoin FL, Merchant RC, Janicki A, et al.: Preventing iatrogenic overdose: A review of in-emergency department opioidrelated adverse drug events and medication errors. Ann Emerg Med. 2015; 65: 423-431.

Gulur P, Koury K, Arnstein P, Lee H, et al.: Morphine versus hydromorphone: Does choice of opioid influence outcomes? Pain Res Treat. 2015; 2015: 482081.

Atluri S, Sudarshan G, Manchikanti L, et al.: Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Phys. 2014; 17: E119-E128.

Hydromorphone-DEA. Available at https://www.deadiversion.usdoj.gov/drug_chem_info/hydromorphone.pdf. Accessed on December 7, 2016.

Dasgupta N, Freifeld C, Brownstein JS, et al.: Crowdsourcing black market prices for prescription opioids. J Med Internet Res. 2013; 16: e178.

Shram MJ, Sathyan G, Khanna S, et al.: Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol. 2010; 30: 25-33.

Wightman R, Perrone J, Portelli I, et al.: Likeability and abuse liability of commonly prescribed opioids. J Med Toxicol. 2012; 8: 335-340.

Jasinski DR: Assessment of the abuse potentiality of morphine-like drugs (methods used in man). In: Martin WR, Drug Addiction I, Springer Publishing, 1977. Available at http://link.springer.com/chapter/10.1007/978-3-642-66612-4_4.

Bickel WK, Bigelow GE, Preston KL, et al.: Opioid drug discrimination in humans: Stability, specificity and relation to self-reported drug effect. J Pharmacol Exp Ther. 1989; 251: 1053-1063.

Hill JL, Zacny JP: Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. Psychopharmacol. 2000; 152: 31-39.

Walsh SL, Nuzzo PA, Lofwall MR, et al.: The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone in prescription opioid abusers. Drug Alcohol Depend. 2008; 98: 191-202.

Bluelight. Available at http://www.bluelight.org/vb/threads/547377-Which-is-better-Heroin-or-Dilaudid. Accessed September 28, 2016.

Erowid. Available at https://erowid.org/pharms/hydromorphone/. Accessed September 28, 2016.

Wightman RS, Perrone J, Erowid F, et al.: Comparative analysis of opioid queries on Erowid.org: An opportunity to advance harm reduction. Subst Use Misuse. 2017; 16: 1-5.

Dean M: Opioids in renal failure and dialysis patients. J Pain Symptom Manag. 2004; 28: 497-504.

Wright AWE, Mather LE, Smith MT: Hydromorphone-3-glucuronide: A more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sciences. 2011; 69: 409-420.

Durnin C, Hind ID, Wickens MM, et al.: Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment. Proc West Pharmacol Soc. 2001; 44: 81-82.

Davison SN, Mayo PR: Pain management in chronic kidney disease: The pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. J Opioid Manag. 2008; 4: 339-344.

Institute for Safe Medication Practices. Error in Lexi-Comp publications within the monograph for hydromorphone dosing. Available at https://www.ismp.org/Errata/comp.asp. Accessed September 28, 2016.

Krajnik M, Zylicz Z: Understanding pruritus in systemic disease. J Pain Symptom Manag. 2001; 212: 151-168.

Kumar K, Singh SI: Neuraxial opioid-induced pruritus: An update. J Anaesthesiol Clin Pharmacol. 2013; 29: 303-307.




DOI: http://dx.doi.org/10.5055/jom.2018.0430

Refbacks

  • There are currently no refbacks.
This site uses cookies to maintain session information critical to the user's experience and environment on this system. Click "Accept Cookies" to continue.
For more details please visit our privacy statement at: Privacy & GDPR